Stakeholder and Supporter of the BMD

Biotechpark Gatersleben Infrastructure GmbH

Bernd Eise, CEO

The Biotechpark Gatersleben Infrastructure GmbH was founded in 2003 as a public-private partnership. 

The Biotechpark Gatersleben - one of the most important locations in plant biotechnology - offers start-ups and enterprises space for their innovative ideas. It covers an area of 100,000 sqm and is a focal point of the biotech offensive in Saxony-Anhalt. It is located on the Biotech-Campus - a broad network involving industry, research and business around the Leibniz Institute of Plant Genetics and Crop Plant Research. The high tech greenhouse, the lab building and the communication building were established in 2006/2007.

Bio-Zentrum Halle GmbH

Dr. Ulf-Marten Schmieder, Sabine Noll, CEO

Since 1993 resp. 1998 the Technology and Founder`s Centre Halle GmbH and the
Bio-Centre Halle GmbH run modern specialist research facilities for biotechnology, biomedicine, medical technology, environmental and process engineering, nanotechnology and also information and automation technology.

Technology orientated start-up companies benefit from office space, laboratories, workshops, greenhouses, animal keeping facilities, GMP areas and clear space in a
total of 9 buildings.

We provide not only classic building and facility management but also support and assistance with planning and implementing investment projects, with organising trade
fair presentations and conferences. We offer project management for research and development projects and facilitate contacts to science and industry.


Europäisches Bildungswerk für Beruf und Gesellschaft gGmbH

Dr. Bernhard Beckmann, Managing director

Das Europäische Bildungswerk für Beruf und Gesellschaft ist Ihr kompetenter Partner für Aus- und Fortbildung. Seit 1990 sind wir an vielen Standorten in Deutschland und Europa tätig. Für Unternehmen der Branchen Biotechnologie, Chemie, Solarindustrie, regenerative Energien, Pharmazie, Ernährungswirtschaft und den Umweltschutz bietet das überregionale Kompetenzzentrum Biotechnologie, Chemie und Umwelt (BCU) eine überbetriebliche Ausbildung in unterschiedlichen Berufen.


Fraunhofer Group “Drug Design and Target Validation”

Prof. Dr. Hans-Ulrich Demuth, Group Leader

The department of Drug Design and Target Validation develops new molecular therapies for neurodegenerative and inflammatory diseases. The department’s expertise is based on an in depth pharma-like understanding of scientific work and a long-lasting experience in the field of drug development. This profile encompasses the identification of new target proteins by analyzing putative pathologic post-translational modifications, the misfolding of proteins and the formation of pathological aggregates. Based on these new strategies the department develops and tests small molecules as well as biological agents (biologicals). 

This research is complemented by the design of new assays for the identification and diagnostic application of biomarkers aiming at monitoring the course of the disease and its therapy. The department’s expertise also expands to the generation of pharmacologically relevant in vitro and in vivo models. Besides state-of-the-art methods for peptide synthesis and protein analytics (MALDI-TOF and LC-MS), the department commands a wide range of biophysical methods to characterize therapeutically relevant physiological pathways, their key proteins as well as cell-based and pharmacologic models for the characterization of new chemical and biological drug candidates.


Gulde & Partner

GULDE & PARTNER is a well-established patent and trademark firm with offices in Berlin, Munich, Hamburg, Halle, Greifswald and Beijing, China. Founded in 1990, our firm is large enough to cover all fields of intellectual property protection but small enough to give individual and careful attention to every case.

Our firm represents your legal interests before the German Patent and Trade Mark Office, the European Patent Office, the Office for Harmonization in the Internal Market in Alicante, German civil and administrative courts, the German Patent Court, the Federal Court of Justice, the European Court of Justice and the International Bureau of WIPO.

We act on behalf of domestic and foreign clients in every aspect of intellectual property protection. The professional advice we offer covers preparing and filing patent and utility model applications, the enforcement and defence of protective rights, matters concerning the German Employee Inventors' Act as well as issues related to trademarks and design patents. Other key areas of our activity are the provision of expert opinions as part of a protective right evaluation, due diligence and the analysis of third-party rights, the drafting of license agreements and the handling of copyright and competition law cases.


Icon Genetics GmbH

Prof. Dr. Yuri Gleba, Founder and CEO

ICON GENETICS discovers and develops new biopharmaceuticals and high-value protein products using green plants as production hosts. We have developed new generation production platforms and product prototypes for pharmaceutical, animal health and chemical biotech markets. We offer new plant engineering technologies which address speed, yield, precision, expression control and safety of transgene management in plants.

So far, ICON GENETICS has generated over 350 FTE-years of research, filed 44 patent applications and exclusively / non-exclusively in-licensed 11 patents. ICON has published a number of milestone research papers in most important peer-review scientific journals.

ICON has built its own GMP-certified facility. Since 2010, ICON runs phase I clinical trials with its first product – individualized vaccine for non-Hodgkin‘s Lymphoma. ICON has a pipeline of cancer antibodies (including several biobetters) and vaccines.

ICON GENETICS is managed by experienced directors and research managers with extensive knowledge of business and corporate research.


IDT Biologika GmbH Dessau-Roßlau

Dr. Ralf Pfirmann, CEO

IDT Biologika operates one of Europe's premiere integrated biological and pharmaceutical development and manufacturing facilities. We are a global supplier to the pharmaceutical and biotechnology industry. With decades of experience developing our own products as well as those of pharmaceutical industry third parties, we understand the needs of our customers when it comes to responsiveness, state-of-the-art technology and integrated solutions. The company has experience in technically sophisticated projects, such as innovative biopharmaceuticals and lyophilized compounds.

The company focuses on four core areas - animal health, human vaccines, pharmaceuticals and quality control: For veterinary markets, IDT Biologika develops, manufactures and markets a comprehensive range of high-quality vaccines and other products for animal health. For vaccines, IDT Biologika offers development services and manufacturing facilities for clinical phase I to III as well as commercial supplies for leading edge viral and bacterial human vaccines. For pharmaceutical markets, IDT Biologika specializes in the development and manufacture of sterile liquid drugs, providing fully-integrated services ranging from formulation development and clinical manufacturing through to large-scale production, packaging and quality control. Our extensive biopharmaceutical quality control services are based on our own innovative research, development and manufacturing. These encompass everything from method development, method transfer, method validation, through to the performance of routine release testing under GMP conditions.  

IDT Biologika is a member of the Klocke Group. The Klocke Group is expert in the areas of innovative packaging solutions and contract manufacturing of solid dosage forms and cytostatics.


IMTM GmbH, Magdeburg

Dr. Michael Täger, Prof. Dr. Siegfried Ansorge, CEO

Based on long-standing experience and excellent competence in the special fields of immunology and internal medicine, IMTM focuses on the development of new drugs for the treatment of widely distributed and so far insufficiently curable diseases,  caused and accompanied by immune dysfunction. Our innovative therapeutic concepts are targeted to peptidase-based immunmodulation -  PETIR™ Drug Design  and thiol-based cytoprotection - ThioTec™.

Two integrated departments provide a comprehensive set of in silico, in vitro and in vivo methods essential for the discovery, optimization and assessment of drug candidates up to clinical trials.

Our scientific and technical staff additionally offers related services for clinical and experimental medicine using the latest technologies in molecular and cell biology as well as in experimental interventional medicine.


Leibniz Institute of Plant Genetics and Crop Plant Research (IPK)

Prof. Dr. Andreas Graner, Managing Director

The Leibniz Institute of Plant Genetics and Crop Plant Research (IPK) is a non-profit research institution and a member of the Gottfried Wilhelm Leibniz Association (WGL). The Institute is the initiator and center of the Biotech Campus Gatersleben in central Germany.

As an internationally renowned plant research center the IPK targets the problems of modern biology in fundamental and applied research by focussing on cultivated plants. 

The central focus of research at the IPK is the study of the genetic diversity of wild and cultivated plants with the aim of making scientific findings, methods and plant material available for more effective and expanded use of plants in the agricultural sector, and also to be a supplier of new and improved biomaterials especially for pharmacy.

The institute draws its strength from  the enormous biological diversity preserved, analyzed and used in its world-famous crop bank, known as Genebank. In addition to this unique biological material the researchers are provided with modern techniques of gene and genome research for the research and analysis of important processes of evolution, development and expression of crops.

The IPK is active in research fields that contribute to a deeper understanding of the molecular genetic and physiological bases of plant characteristic value and plant performance. Our three interdisciplinary research areas:

  • Resources research
  • Genome research
  • Molecular Plant Physiology


Nomad Bioscience GmbH Halle (Saale)

Prof. Dr. Yuri Gleba CEO

The Nomad Bioscience GmbH was founded in 2008. In 2012, its subsidiary Icon Genetics GmbH, which was founded already in 1999, was acquired from Bayer AG. In Saxony-Anhalt, an experienced scientific and management team with proven track record (33 full-time employees including 28 scientists, therefrom 15 PhD’s) is working at Nomad.

Nomad has developed a Plant-Based Transient Expression Technology Platform for multiple markets. These markets are food safety, industrial, healthcare and agronomic traits. Nomad has a strong intellectual property position, which gives freedom to operate for production processes. There is a favorable regulatory environment: successful phase 1 trial in 2013; US field trials in 2014; GRAS approval projected in 2015.


Nordsaat Saatzucht GmbH Böhnshausen-Langenstein

Wolf von Rhade, Claus-Henning von Rhade, CEO

Thanks to our successful breeding programmes, we have already pointed the way to the future. Three breeding stations located on approximately 150 ha of plant breeding garden are used for the further development of high-yield varieties of winter wheat, hybrid wheat, triticale, winter and spring barley and oats.

Along with six other medium-sized plant breeders, Nordsaat is an associate of SAATEN-UNION. In addition to jointly selling varieties through Saaten-Union, individual associates coordinate their breeding, testing and production activities across Europe and offer a wide range of cultivated species with a focus on international markets.


Probiodrug AG Halle (Saale)

Dr. Konrad Glund (CEO), Hendrik Liebers (CFO)

Probiodrug AG is a biopharmaceutical company focused on the development and commercialisation of new therapeutic products for the treatment of Alzheimer’s disease (“AD”). 

Headquartered in Halle, Germany, Probiodrug was founded in 1997 by Prof Dr. Hans-Ulrich Demuth and Dr. Konrad Glund and successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors / gliptins. Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s treatments and to thereby provide a better life for patients.

Probiodrug has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight AD.


S.E.T. Technology GmbH

Dr. Thomas Hermsdorfer

The structure of SET is based on three major technology areas. Each division works with specialized consultants, headed by technology experts. Our consultants accompany the projects as a part of active management over the period from proof of concept to an existing, market placed company which is ready for long term investments, or alternative exit strategies. All divisions are part of SET Technology GmbH. The parent company provide the back office service, network with our inventors and innovation providers as well with our international partners.

SET will oversee and manage the end-to-end process: „Portfolio Building“ (building and decorating the window), preparing for presentation and decision for execution (start-up investment). „Portfolio Building“ will be handled in close collaboration with our R&D partners to establish a robust pipeline of initiatives. The subsequent execution will be managed by project managers, thus monitored and supported by SET.


Trait Genetics GmbH

Dr. Martin Ganal, CEO

TraitGenetics addresses an increasing demand for molecular marker development and analyses in plant breeding and biodiversity research.

The company was established in 2000 by Dr. Martin Ganal and became operational in January 2001. TraitGenetics is an independent company that is exclusively owned by Dr. Martin Ganal and some key employees of the company. After more than seven years in business, TraitGenetics is meanwhile a profitable company with a large number of customers.  

TraitGenetics is specialized in the development and analysis of many types of molecular markers (predominantly microsatellites and SNPs) for biodiversity and plant breeding research. This includes the use of molecular markers for the construction of genetic maps, marker-assisted selection in large populations, the construction of molecular marker databases for plant variety identification and germplasm characterization as well as map-based cloning.



Herr Joachim von Kenne, CEO

The Centre for Neuroscientific Innovation and Technology (ZENIT) was founded with the aim of using the neuroscientific site at Magdeburg to transfer its basic knowledge into marketable product development. ZENIT generates innovation in the Saxony-Anhalt economy using the university as a conduit, thereby contributing to an important development of a regional industrial structure on a long term basis. ZENIT was founded together with a municipal provider as an independent institution within the university, renting out research areas to institutions cooperating with the university, commercial research companies as well as university institutions. The interdisciplinary research building provides space and equipment for third-party funded and industry-sponsored research projects. ZENITs medical as well as medical-technical research are aimed at innovation and technology development. The most important neuroscientific topics of ZENIT are neuropharmacology, neuromedical technique and applied neuro-computer-science. Within ZENIT medical-technology orientated companies (e.g. pharmaceutical industry, manufacture of medical devices etc.) will establish work groups which intend to realise specific and defined research and development projects independently or in cooperation with the medical faculty. ZENIT also laid the foundations for the formation of companies which developed out of the university (start-up companies).